Enoblituzumab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Enoblituzumab 是一种人源化 IgG1κ 单克隆抗体，可以识别人 B7-H3 蛋白 (B7 家族的免疫调节剂成员)。

Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators.

Enoblituzumab interacts with B7-H3 and causes strong antibody-dependent cellular cytotoxicity (ADCC) against a wide spectrum of cancer cells.Enoblituzumab (0.01 ng/mL-10 mg/mL) mediates antibody-dependent cellular cytotoxicity (ADCC) against A498 cells with cynomolgus monkey peripheral blood mononuclear cells (PBMCs).

Enoblituzumab (5 mg/kg; i.v.; single dose) exhibits estimated half-life of 249 hours with a Cmax of 43 mg/mL in mice (mCD16-/-hCD16A+) that murine CD16 gene knocked out and are transgenic for human CD16A-158F.Enoblituzumab (0.1-10 mg/kg; i.v.; once weekly; 5 weeks) exhibits potent antitumor activity in B7-H3-expressing xenograft mice models of renal cell and bladder carcinoma.Animal Model:mCD16-/-hCD16A+ mice implanted with A498 renal cell carcinoma, 786-0 renal cell carcinoma, or HT-1197 bladder carcinoma cells (s.c.) Dosage:1 mg/kg, 5 mg/kg, 10 mg/kg Administration:Intravenous injection; once weekly; 5 weeks Result: Significantly inhibited tumor growth at doses of 1 mg/kg or greater with once weekly treatment.Achieved a cytostatic response at 5 or 10 mg/kg until day 52, after which the average tumor volume of the 5 mg/kg treatment group remained near predose administration levels, whereas a nonsignificant trend toward relapse exhibited in the 10 mg/kg group.

——

Others

Other Targets

Others

——

——

1353485-38-7

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years